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Abstract Chronic cluster headache (CCH) is a disabling
primary headache, considering the severity and frequency
of pain attacks. Deep brain stimulation (DBS) has been
used to treat severe refractory CCH, but assessment of its
efficacy has been limited to open studies. We performed a
prospective crossover, double-blind, multicenter study
assessing the efficacy and safety of unilateral hypothalamic
DBS in 11 patients with severe refractory CCH. The ran-
domized phase compared active and sham stimulation
during 1-month periods, and was followed by a 1-year open
phase. The severity of CCH was assessed by the weekly
attacks frequency (primary outcome), pain intensity,
sumatriptan injections, emotional impact (HAD) and
quality of life (SF12). Tolerance was assessed by active
surveillance of behavior, homeostatic and hormonal func-
tions. During the randomized phase, no significant change
in primary and secondary outcome measures was observed
between active and sham stimulation. At the end of the
open phase, 6/11 responded to the chronic stimulation
(weekly frequency of attacks decrease [50%), including
three pain-free patients. There were three serious adverse
events, including subcutaneous infection, transient loss of
consciousness and micturition syncopes. No significant
change in hormonal functions or electrolytic balance was
observed. Randomized phase findings of this study did not
support the efficacy of DBS in refractory CCH, but open
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phase findings suggested long-term efficacy in more than
50% patients, confirming previous data, without high
morbidity. Discrepancy between these findings justifies
additional controlled studies (clinicaltrials.gov number
NCT00662935).
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Introduction
Cluster headache (CH) is a primary headache and belongs to
the group of the trigeminal autonomic cephalalgias in the
International Classification of the Headaches Disorders
[1–3]. CH mainly affects men and is characterized by strictly
unilateral short-lasting pain attacks associated with promi-
nent parasympathetic features. Episodic CH affects 80–90%
of patients who describe periods of attacks (cluster) and
periods of remission. Chronic CH (unremitting from onset or
evolved from episodic form) lacks the remissions and is
diagnosed after 1 year without remission or with remission
periods lasting less than 1 month [2]. CH is one of the most
painful conditions in humans and is often referred to as
‘‘suicidal headache’’. The pathophysiology of CH revolves
around the trigeminal-autonomic reflex whose activation
explains the trigeminal topography of pain and the ipsilateral
autonomic features [4]. Functional imaging demonstrated a
brain activation during attacks [5], co-localized with a
structural change, in the posterior hypothalamic region. [6].
This prompted the use of deep-brain stimulation (DBS) to
modulate this region in a patient with refractory chronic CH
which led to complete relief from attacks [7]. Based on this
observation, DBS was introduced in the treatment of medi-
cally refractory chronic CH. After 8 years of experience,
DBS is claimed to be successful in controlling the pain
attacks in about 60% of the 41 chronic CH patients implanted
worldwide [8–14]. Yet such a claim may be debatable con-
sidering the absence of formal blinded controlled study.
Here, we report the first randomized, double-blind, cross-
over study comparing DBS (stimulation ‘‘On’’) of the pos-
terior hypothalamic region with a sham control (stimulation
‘‘Off’’), followed by a 10-month open phase (stimulation
‘‘On’’) with a special focus on the procedure’s safety.
Methods
Patients
Patients with refractory chronic CH were enrolled in the
study according to the following inclusion criteria: chronic
CH according to ICHD-II criteria [2]; disease duration over
3 years; resistance to pharmacological prophylactic treat-
ment with adequate trials (verapamil up to 960 mg/day,
lithium with plasma level from 0.6 to 1 mEq/l, association
of both; in absence of adverse events); daily attacks;
absence of substance abuse or dependence; age 18–65-
year-old; normal findings on magnetic resonance imaging;
no contraindications to surgery or anesthesia.
Study design
This study consisted of a randomized, double-blind,
crossover design with two 1-month periods separated by a
1-week wash-out period and an extension 10-month open
phase (Fig. 1). The trial was conducted in four academic
centers in accordance with the Declaration of Helsinki, and
was approved by the ethics committee of the Nice Uni-
versity Hospital (Comite´ de Protection des Personnes Sud
Me´diterrane´e V). All centers associated a neurological
team belonging to the ‘‘Observatoire des Migraines et
Ce´phale´es’’ set up by the French Headache Society [15]
and a neurosurgical team highly qualified in the DBS
domain and pain management.
All patients provided written informed consent. Eligible
patients were randomly assigned in a 1:1 ratio to one of the
two groups; either active stimulation followed by a sham-
stimulation period (On–Off) or the reverse other (Off–On).
Previous studies [9, 11, 12] demonstrated that posterior
hypothalamic stimulation does not induce perceptible
sensations, allowing double-blind trial as the patient is not
able to identify the ‘‘on’’ or ‘‘off’’ condition. We used a
blocking scheme randomization and a central randomiza-
tion procedure without stratification. Stimulation parame-
ters were set up by the neurosurgeon. The 1-month duration
of the randomized periods was defined according to the
data available when the study was designed. At that time,
in 2003, in the study of Franzini et al. [9], ‘‘pain disap-
pearance … occurred after few hours in 2 cases and later
(1–4 weeks) in the other 3 cases’’. In the study of Schoenen
et al. [11], ‘‘all patients improved 2 weeks after implanta-
tion’’. Clinical evaluation was performed by the neurologist
blinded of the stimulation status. At each evaluation,
clinical data collected were: number of attacks during the
last week (calculated from the individual patient’s diary),
mean attack intensity during the last week (according to
Likert scale), number of subcutaneous sumatriptan
administration during the last week (from the patient’s
diary), oxygen use (yes or no), anxiety and depression
levels (Hospital Anxiety Depression scale), quality of life
(SF-12 scale), supine and standing blood pressure, heart
rate, weight and body temperature. Electrolyte balance and
hormonal functions (thyroid hormones, TSH, ACTH, cor-
tisol, SDHEA, insulin, prolactin, testosterone, estradiol,
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LH, FSH, GH and IGF-1) were evaluated at each evalua-
tion. After surgery, evaluations additionally included:
patient’s satisfaction (Patient’s Global Impression of
Change) and changes in thirst, appetite, libido, sleep-
walking cycle and behavior. Any new symptom or wors-
ening of a preexisting symptom was classified as an
adverse event. An adverse event was classified as serious in
case of death, hospitalization, sequel or consideration as
serious by the clinician. According to the study protocol,
prophylactic treatment was held constant during the ran-
domized phase, but could be adapted during the open
phase.
Surgery and stimulation
The posterior hypothalamus was targeted on preoperative
3D MRI, according to previously published coordinates,
namely 2 mm lateral to the midline, 3 mm posterior and
5 mm below the mid-commissural point [9]. The four-
contact electrode (model 3389 DBS, Medtronic) was
implanted stereotactically (deepest contact on the target),
ipsilateral to the pain side, under local anesthesia, without
intraoperative micro-recording (Fig. 2). Intraoperative test
stimulation (up to 3 V) was conducted through this elec-
trode before its fixation to check any side effect. The elec-
trode location was confirmed by postoperative 3D
neuroimaging before its connection to the pulse generator
(Kinetra, Medtronic), implanted under general anesthesia.
Optimal stimulation parameters were defined by the neu-
rosurgeon during the week following surgery before the
randomization. The closest contact from the theoretical
target on postoperative imaging was used for stimulation in
the randomized phase. Stimulation frequency and pulse
duration were, respectively, 185 Hz and 60 ls. Voltage was
individually adjusted according to side effects investigated
by increasing voltage: 3 V by default or 80% of the
threshold producing side effects. These stimulation param-
eters were kept constant during all along the randomized
phase, but could be changed during the open phase.
Outcome and statistical analysis
All outcome measures were analyzed by intention to treat.
We performed a crossover analysis for the On and Off
periods. Primary outcome was the number of attacks during
the last week of each period, according to the International
Headache Society guidelines for controlled trials of drugs
in CH [16]. Secondary outcomes were the number of
subcutaneous sumatriptan administration during the last
week, intensity of attacks, satisfaction of patients, HAD
sub-scores and SF-12 scores. Review of the early DBS
studies [9, 11] in CH, available when the present study has
been designed, did not allow to find the mean and vari-
ability of our primary outcome, namely frequency of
attacks per week, in this refractory CH patients candidates
for surgery. Due to absence of published data, this estimate
was based on the characteristics of refractory chronic CH
patients registered in the Nice University Hospital data-
base. Power calculation was based on our estimate that at
baseline mean weekly frequency of attacks would be 23.9
(SD 3.7). The study was designed to have an overall power
of 90% to detect a 50% reduction of the primary endpoint
during the stimulation period. According to Jones and
Kenward [17], three effects were tested: carry-over, period
Fig. 1 Design of the study. The randomized phase of the study
included two 1-month treatment periods (week 8 to week 12 and week
13 to week 17) separated by a 1-week washout period. Patients were
evaluated at inclusion, 1 week before surgery; 4 weeks after surgery
(before active or sham stimulation) and at the end of the first
randomization period (weeks 12 and 17). This randomized phase was
followed by a 10-month open phase. Patients were evaluated at the
end of this phase (week 52)
J Headache Pain (2010) 11:23–31 25
123
and treatment effects. Type I error was fixed at 10% for the
carry-over effect and 5% for the others. Non-parametric
two-sided Wilcoxon rank-sum tests were used for the
analysis, given the number of patients. The effect of
treatment at 1 year compared to baseline was done with a
Wilcoxon test for paired samples (two-sided, type I error
rate = 5%) on primary and second outcomes. All the sta-
tistical analysis was performed using the SPSS version 11.0
program (SPSS Inc., Chicago, IL, USA).
Results
Study population
Twelve patients were included (May 2005–June 2007), 1
declined to participate, 11 were operated, 1 was explanted
due to infection but re-implanted later, before the ran-
domization. Consequently 11 patients completed the ran-
domized phase and the open phase. Pre-implantation
clinical characteristics of these 11 patients are shown in
Table 1. According to the inclusion criteria, the patients
included were non-responders to verapamil and lithium.
However, considering the duration of chronic CH, all these
patients have been previously treated in sufficient dosages
(unless contraindicated or unacceptable side effects) alone
or in combination by gabapentine, indometacine, methy-
sergide, pizotifen, topiramate, steroids and valproate, and
were considered as non-responders. There was no signifi-
cant difference in these characteristics between the two
groups (On–Off and Off–On).
Effect of electrode implantation
Mean stereotactic coordinates (SD) of the deeper contact of
the electrode relative to the mid-commissural point were
x = 2.20 (0.83), y = -3.24 (1.83) and z = -3.69 (1.71).
There was no significant change in the mean weekly fre-
quency of attacks after implantation compared to baseline,
although two patients (C1P4 and C4P1) still showed a
‘‘lesion effect’’ (decrease C50%) 1 month after surgery.
Effect of the stimulation during the randomized phase
At the end of the randomized phase, patients and neurol-
ogists were not able to identify their period allocation,
confirming the double-blind evaluation. The weekly fre-
quency of CH attacks did not significantly differ between
the On and Off periods (Table 2). We did not detect any
significant carry-over effect (P = 0.855) indicating that the
effects of the first treatment period did not persist after the
wash out. None of the secondary outcomes differed
between stimulation and sham treatment. Stimulation
voltages used during the randomized phase ranged from 1.0
to 2.8.
Effect of the stimulation during the open phase
At the end of the 10-month open phase, the mean weekly
attacks frequency decreased by 48.4% (P = 0.08) and
emotional impact was significantly reduced (Table 3).
Other secondary outcomes did not change significantly. Six
out of 11 patients were considered as responders (at least
50% decrease in weekly attacks frequency), including three
pain-free patients (Fig. 3). Among these 6 patients, pro-
phylactic treatment was stopped or dose-decreased C50%
in 2, unchanged in 2 and modified in 2 (Table 4). We did
not identify any predictive factor of efficacy in this small
population, concerning clinical characteristics, stimulation
parameters or electrode location.
Fig. 2 Postoperative tridimensional MRI (patient C1P4), T1
weighted images after gadolinium injection, axial (a) and saggital
(b) slices, showing the location of the stimulating contact (white
circle) within the black artifact generated by the electrode. Dotted line
indicates the projection of the electrode trajectory on the slice
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Adverse events
Three serious adverse events were reported during the
study, in two patients. One subcutaneous infection,
3 weeks after surgery, completely resolved after hard-
ware removal and antibiotic treatment. The patient was
re-implanted 6 months later. One patient experienced a
preoperative loss of consciousness with hemiparesia
shortly after test stimulation. An immediate CT-scan was
normal. Symptoms spontaneously resolved in 2 h without
sequel. During the open phase, the same patient reported
multiple severe micturition syncopes associated with
decrease of blood pressure in standing position.
Twenty-six non-serious adverse events (NSAE) were
reported (Table 5). All of them were mild, and most of
them were transient. Rates of NSAE were similar in both
‘‘On’’ and ‘‘Off’’ randomized periods. Compared to base-
line, no change in electrolyte balance and hormonal levels
were detected, except a testosterone level increase,
observed in one patient during the ‘‘off’’ period and open
phase. According to behavioral systematic auto-evaluation,
7/11 patients reported a ‘‘calming effect’’ at the end of the
open phase, compared to baseline.
Discussion
In the controlled phase of this study, we failed to dem-
onstrate that DBS improved chronic CH when compared
with sham stimulation. These findings contrasted with the
results observed in the open phase of the study, which
showed that more than 50% of the patients were
improved over 50%, and that mean attack frequency and
emotional impact were markedly decreased. Our long-
term results were similar with the overall outcome of the
38 patients with chronic CH previously implanted in non-
controlled conditions, showing that about 60% of them
were improved over 50% [10, 14]. This improvement
observed in the open phase was unlikely due to natural
variations of the severity of chronic CH, because the
attack frequency had been stable for more than 3 years
before the inclusion in the study. Open phase improve-
ment was unlikely due to prophylactic treatment changes
because in four out of six responders, this treatment was
stopped, dose-decreased or unchanged. However, the
improvement observed at the end of the open phase could
be related to a sustained placebo effect, sometimes
described in headache trials [18]. Although one could
speculate that DBS is ineffective in chronic CH, several
bias, mainly related to the study design, might explain
that efficacy of DBS has not been demonstrated in the
randomized phase. First, the small sample size could have
lead to inconclusive results in the randomized phase. Due
to the lack of published data concerning this sub-popu-
lation of refractory chronic CH patients, sample size
calculation was based on the estimation of characteristics
of these CH patients, registered in our institution data-
base. Considering that the variability of weekly attack
frequency was higher in the included population (SD:
13.2) than the estimated one (SD: 3.7), the sample size
calculation might be a posteriori not adequate. Second,
early publications, available when the study protocol has
been written, mentioned that the delay between the
stimulation onset and the therapeutic effect was less than
4 weeks, allowing to design a trial with 1-month periods
[9, 11]. In later publications, this delay was longer (mean




















C1/P1 On/Off M 52 35 Left Episodic 14 9 1 No
C1/P2 Off/On M 40 12 Right Chronic 14 5 14 No
C1/P3 Off/On M 51 8 Left Episodic 19 2 15 No
C1/P4 On/Off M 44 10 Left Chronic 28 10 0 No
C1/P5 On/Off M 47 7 Right Chronic 11 6 11 No
C2/P1 Off/On M 50 20 Right Episodic 20 5 0 No
C2/P2 Off/On F 42 3 Left Chronic 7 8 1 Yes
C3/P1 On/Off F 42 7 Right Episodic 53 6.5 0 Yes
C3/P2 Off/On M 36 7 Left Chronic 9 5 11 No
C4/P1 Off/On M 39 18 Right Episodic 14 5 14 No
C4/P2 On/Off F 43 6 Right Chronic 7 7 1 Yes
Mean 44.1 12.1 17.8 6.1 6.2
Some patients did not use attack treatment by sumatriptan and/or oxygen due to their lack of efficacy or side effects (such patients used opioids
with weak efficacy)
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42 days) [19]. Consequently, a 1-month period might be
too short to observe a significant improvement. Finally,
stimulation parameters used during the randomized phase
were set by default, based on the ones previously reported
[9, 11]. During the open phase, tedious individual ‘‘trial
and error’’-based adjustment of these parameters allowed
to reach the expected efficacy. Consequently, the ran-
domized phase might have been conducted using non-
optimal parameters in some patients. Considering these
possible biases, we proposed (after approval of the ethical
committee) to the six responders in the open phase to be
included in a new randomized phase, consisting in
switching off the stimulator in control and double-blind
conditions. All of them refused, fearing to loose the
therapeutic effect.
DBS for CH appeared to be relatively safe in this study.
No intracranial hemorrhage occurred, although this com-
plication has been reported in early studies [11, 19]. In
contrast to these studies, we did not use microelectrode
recording in order to decrease the risk of bleeding, prob-
ably higher in this region. The most frequent adverse
events (mainly visual disturbances) were stimulation-rela-
ted and disappeared with stimulation parameters adjust-
ment. Transient hemiparesia and loss of consciousness
occurred during test stimulation in one patient, as in one
case described by Starr et al. [12]. Micturition syncopes
observed in one patient were probably related to changes in
autonomic responses on cardiovascular system induced by
chronic DBS [20]. No other clinically significant changes
in homeostatic and hormonal functions were observed





End of open phase
(week 52)
Median [range]
Difference between end of
open phase and baseline
Mean [95% CI]
P value
Attacks/week 14 [7; 53] 8 [0; 23] 8.16 [–18.3; 34.7] 0.082
Pain intensity 6 [2; 10] 4.5 [0; 10] 1.1 [–7.1; 9.3] 0.499
Sumatriptan
(injections/week)
1 [0; 15] 0.5 [0; 26] –0.1 [–11.3; 11.1] 0.288
HAD-A 13 [5; 18] 7.5 [0; 14] 6.3 [–5.1; 17.7] 0.008
HAD-D 10 [1; 16] 4.5 [1; 15] 4.1 [–6.48; 14.7] 0.052
SF12-MS 33.2 [27.5; 53.3] 37.0 [20.7; 56.6] –0.6 [–26.5; 25.2] 0.953
SF12-PS 32.7 [24.4; 46.5] 39.7 [25.2; 50.5] 4.3 [–16.7; 25.3] 0.173
Severity of chronic CH has been assessed by weekly attack frequency, pain intensity (Liekert scale), and weekly sumatriptan injections, during
the last week before surgery and at the end of the open phase. Emotional impact was assessed by the French version of the widely used Hospital
Anxiety and Depression scale (HAD). The HAD involves seven anxiety items alternating with seven depression items. Anxiety and depression
are defined by anxiety (HAD-A) and depression (HAD-D) scores superior to 7, respectively. The health-related quality of life was evaluated
using the French version of the short-form 12 questionnaire (SF12) used to derive to summary scores, physical (SF12-PS) and mental (SF12-MS)
component summaries. Lower numbers indicate greater disability
Fig. 3 Individual changes in
weekly attack frequency in the
11 patients between baseline
(before surgery) and the end of
the open phase
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despite an active surveillance of harms based on structured
questionnaires and diagnostic tests performed at pre-spec-
ified time intervals all along the study.
CH has been described as the most painful primary
headache, with a risk of suicide during attacks, justifying
the moniker of ‘‘suicide headache’’ [21]. Considering our
inclusion criteria and the patients’ history (see ‘‘Study
population’’), all the patients included in our study fulfilled
the criteria of intractable CH defined by international
experts panels [22, 23], except for melatonin use (not
available in France). In such patients, due to pain severity,
absence of remission and treatment resistance, surgery may
be a feasible option for pain control. Consequently, con-
sidering the safety and long-term outcomes of DBS in our
study, the balance of benefit and harms may be considered
as positive. This justifies to further evaluate DBS in addi-
tional controlled studies, using longer randomized periods
or an initial open phase allowing enriched enrollment fol-
lowed by a randomized phase. Predictors of outcome
(headache characteristics, responses to medication and
functional imaging features) need to be identified in order
to select the potential responders [24]. However, future
DBS studies should take into consideration the recent
development of less invasive procedures, as occipital nerve
subcutaneous stimulation (ONS) [25, 26]. Although the
ONS efficacy remains to be confirmed in controlled con-
ditions, DBS may be reserved for failure of ONS.
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